Pyrimidine biosynthesis inhibitors synergize with nucleoside analogs to block SARS-CoV-2 infection

The ongoing COVID-19 pandemic has highlighted the dearth of approved drugs to treat viral infections, with only ∼90 FDA approved drugs against human viral pathogens. To identify drugs that can block SARS-CoV-2 replication, extensive drug screening to repurpose approved drugs is underway. Here, we sc...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:bioRxiv
Main Authors: Schultz, David C., Johnson, Robert M., Ayyanathan, Kasirajan, Miller, Jesse, Whig, Kanupriya, Kamalia, Brinda, Dittmar, Mark, Weston, Stuart, Hammond, Holly L., Dillen, Carly, Castellana, Lauren, Lee, Jae Seung, Li, Minghua, Lee, Emily, Constant, Samuel, Ferrer, Marc, Thaiss, Christoph A., Frieman, Matthew B., Cherry, Sara
Formato: Artigo
Idioma:Inglês
Publicado em: Cold Spring Harbor Laboratory 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8240684/
https://ncbi.nlm.nih.gov/pubmed/34189531
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2021.06.24.449811
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados